Actively Recruiting
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Led by Dana-Farber Cancer Institute · Updated on 2025-07-10
500
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the inherited risk factors that may contribute to lung cancer, especially among people who have minimal tobacco exposure. This study focuses on individuals and families with known genetic mutations or family histories suggesting a hereditary risk for lung cancer. It aims to better understand how genetic susceptibility influences lung cancer development and to observe the natural progression of the disease in these populations. Participants include those known or suspected to carry germline mutations in the EGFR gene or other genes associated with lung cancer. The study also includes individuals with family histories of lung cancer but no identified germline mutation. The research involves collecting genetic and clinical information, including blood or saliva samples, questionnaires, and access to medical records and tissue samples. Participants may provide blood samples annually for up to five years, and family member contacts may also be collected. During the study, participants will undergo eligibility screening, medical record reviews, and complete short questionnaires. Researchers will collect biological specimens and may use stored tissue samples or medical data from deceased relatives with consent. The study will measure the prevalence of rare genetic mutations linked to lung cancer and track lung cancer histories and lung nodule prevalence over three years. This observational study expects to enroll about 500 people and is designed to build a data and specimen repository to improve risk prediction and understanding of hereditary lung cancer.
CONDITIONS
Brief Title
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Individuals with or at high risk of carrying an EGFR germline variant identified by genetic testing
- Individuals with or at high risk of carrying non-EGFR germline variants linked to inherited lung cancer risk
- Individuals with lung cancer and a family history of lung cancer or personal history of multiple primary lung cancers
- Blood relatives of eligible individuals, including presumed carriers and healthy controls
- Deceased patients with available pathology specimens and medical records with next-of-kin consent
You will not qualify if you...
- Individuals who decline to consent
- Individuals unable to give consent or assent without a healthcare proxy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants provide blood and/or saliva samples, answer questionnaires, and may consent to use of tissue samples, access to relatives' medical records, and sharing contact information of family members to help researchers study genetic risks and natural history of lung cancer.
Annual visits for blood sample collection and ongoing data updates
Trial Site Locations
Total: 2 locations
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Not Yet Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
J
Jaclyn LoPiccolo, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here